Effect of Celecoxib in the prevention of pancreatitis after Endoscopic retrograde cholangiopancreatography (ERCP)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201207252417N8

Enrollment

Registered

2012-08-06

Start date

2012-04-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pancreatitis. Other acute pancreatitis

Interventions

Intervention 1: Cap celecoxib 100mg, 3 capsuls. Sajjad Pharmaceutical Company, Mashad. 5 hours before Endoscopic retrograde cholangiopancreatography. Intervention 2: Cap Placebo, 3 capsuls. Sajjad Pha

Treatment - Drugs

Placebo

Cap celecoxib 100mg, 3 capsuls. Sajjad Pharmaceutical Company, Mashad. 5 hours before Endoscopic retrograde cholangiopancreatography

Cap Placebo, 3 capsuls. Sajjad Pharmaceutical Company, Mashad. 5 hours before Endoscopic retrograde cholangiopancreatography

Eligibility

Sex/Gender

All

Age

15 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- no advanced systemic disease 2- no addiction 3- no continouse drug use 4- mild hepatobilliary disease with liver enzyme elevation to 4 times of normal upper limit. 5- without fibrosis, cirrhosis or infectious hepatitis exclusion criteria: 1- other side effects except pancreatitis after ERCP 2- Lack of consent to cooperate in trial.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pancreatitis. Timepoint: Befor and 2 hours after Endoscopic retrograde cholangiopancreatography. Method of measurement: Pain and clinical signs.;Serum amylase level. Timepoint: Befor and 2 hours after Endoscopic retrograde cholangiopancreatography. Method of measurement: ELISA kits: International Unit per Littre.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr zhaleh derakhshan

Isfahan University of Medical Science

mona.derakhshan@yahoo.com+98 31 1668 5555

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026